ABT 110
Alternative Names: ABT-110; HU αD11; Hu-alpha-D11; HuAlphaD11; PG-110Latest Information Update: 05 Feb 2013
At a glance
- Originator Lay Line Genomics
- Developer AbbVie
- Class Analgesics; Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Back pain; Pain
Most Recent Events
- 26 Jan 2013 Discontinued - Phase-II for Pain in Argentina (IV)
- 26 Jan 2013 Discontinued - Phase-II for Pain in Australia (IV)
- 26 Jan 2013 Discontinued - Phase-II for Pain in Germany (IV)